ranolazine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Djamgoz, MBA; Fraser, SP; Pires, W; Qiu, S | 1 |
| Djamgoz, MBA; Fraser, SP; Lee, A | 1 |
2 other study(ies) available for ranolazine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine.
Topics: Adenosine Triphosphate; Cell Line, Tumor; Humans; Ion Channels; Minoxidil; Ranolazine; Triple Negative Breast Neoplasms | 2022 |
Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA-MB-231 breast cancer cells: Effects of combination with ranolazine.
Topics: Cell Movement; Cell Proliferation; Collagen; Drug Combinations; Female; Gene Expression Regulation, Neoplastic; Humans; Laminin; NAV1.5 Voltage-Gated Sodium Channel; Neoplasm Invasiveness; Potassium Channels, Voltage-Gated; Propranolol; Proteoglycans; Ranolazine; Receptors, Adrenergic, beta; Triple Negative Breast Neoplasms; Tumor Hypoxia | 2019 |